What We're Reading: Drug Imports; Insurers See ACA Profits; Alzheimer's Forecast
How counties, cities, and schools are saving money by importing drugs for employees; insurers are finally turning a profit on their Obamacare plans; new report projects the number of Americans with Alzheimer's disease will more than double by 2060.
What We're Reading: Entitlement Reform; Medicaid Surplus in La.; Pace of ACA Sign-Ups
House Speaker Paul Ryan, R-Wisconsin, is eyeing spending cuts to Medicare and Medicaid; Louisiana's Medicaid program reported lower-than-expected spending and a potential surplus; ACA enrollment continues to climb, but expected to fall short of 2017 due to shorter enrollment period.
What We're Reading: More Healthcare Mergers; Expedited FDA Review; $102M CMS Billing Issue
Humana may also make an acquisition deal and UnitedHealth buys a unit of DaVita; a look at the FDA's expedited review programs; how a billing code discrepancy may have cost taxpayers up to $102 million in Medicare payments to hospitals.
What We're Reading: ACA Funding and Stabilization; Recycling Drugs; Medications for Pregnant Women
Senator Susan Collins, R-Maine, makes her tax bill vote contingent on more Obamacare funding; some states are setting up programs to recycle leftover drugs; and pregnant women deal with medication uncertainty.
What We're Reading: Uterine Transplant Birth; Opioid Treatment; Curbing HIV
A woman gives birth after receivng a uterine transplant for the first time in the US; a once-monthly treatment for patients with poioid addiction gains FDA approval; and LA public health officials launch an initiative to reduce the annual number HIV infections.
What We're Reading: Flu Season; Offsetting Sedentary Lifestyle; Short-Term Health Plans
Flu season in North America is off to an early start; exercising regularly might not offset a generally sedentary lifestyle; short-term health plans are being packaged to circumvent Obamacare restrictions.
What We're Reading: Azar's Confirmation Hearings; New Opioid Czar; Long-Term Impact of Trauma
Alex Azar faces skepticism regarding his ability to regulate drug prices given his past employment; Kellyanne Conway is named America's opioid czar; a study finds childhood trauma can have a generational impact.
What We're Reading: Skinny Health Plans; Work Travel Health Issues; Lacking Computer Skills
New skinny plans cause confusion in the healthcare marketplace; the health risks associated with frequent travel need to be studied more; a doctor lacking computer skills loses license to practice.
What We're Reading: CHIP's Crunch; Healthcare Odd Couples; ACA Sign-Ups Slow
Some states prepare to end the Children's Health Insurance Program with no new funding; shifting healthcare landscape reveals odd partnerships; Affordable Care Act sign-ups slow in third week of open enrollment.
AHRQ and ECRI Launch New Guideline Assessment Tool
A new tool developed by the Agency for Healthcare Research and Quality and the ECRI Institute will assess the extent to which a guideline adheres to the Institute of Medicine’s (IOM) standards for trustworthy evidence-based clinical guidelines.
What We're Reading: Surprise Ambulance Bills; Brexit's Health Impact; Antibiotic Resistance Threat
Patients might be able to avoid or better manage surprise ambulance bills; Brexit causes providers to leave London and prevents others from entering Britain at all; new research provides insight on antibiotic resistance.
What We're Reading: End-of-Life Discussions; New Opioid Guidance; Missouri's HCV Drug Policy
This Thanksgiving, families will discuss of end-of-life care wishes; FDA provides new guidance for development of abuse-deterrent opioids; Missouri reverses its restrictive policy in Medicaid for hepatitic C medicine.
Consequences and Outcomes of Consolidation in Dermatology Driven by Private Investors
Consolidation is happening all throughout the healthcare industry in the United States, but the shift to consolidation in dermatology began to pick up speed in just the last 3 to 5 years and it has been driven by private investors, according to a new Viewpoint in JAMA Dermatology.
What We're Reading: Private Care in VA; Arizona Medicaid Expansion; Parkinson's Drug Update
VA Secretary David Shulkin wants the private sector to play a larger role in veterans' healthcare; Arizona's Supreme Court ruled in favor of a component to keep the state's Medicaid expansion; Acorda ends drug development of tozadenant for Parkinson's disease.
Determining the Risk of Chemotherapy-Induced Neutropenia to Guide Use of Colony-Stimulating Factors
A recent abstract presented at the American Society of Clinical Oncology (ASCO) annual meeting compared 2 risk models for patients with intermediate chemotherapy-induced neutropenia (CIN) risk and compared them to guidelines from ASCO and the National Comprehensive Cancer Network to determine when colony-stimulating factor should be ideally used to prevent CIN. ​​​​​​
What We're Reading: Mandate Repeal Uncertainty; Destroying Antitrust Evidence; PTSD After Cancer
The White House indicated willingness to leave the individual insurance mandate in place in tax reform legislation; California health system Sutter Health was accused of intentionally destroying 10 years of records related to an antitrust lawsuit; and a new study indicates over 1 in 5 patients develops posttraumatic stress disorder in the months after a cancer diagnosis.
ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy
With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.
What We're Reading: Gene Therapy Guidelines; Opioid Overdose Costs; Unaware of Open Enrollment
The FDA issued new guidelines to speed up the review process for gene therapies; a new report calculates the potential societal benefits of eliminating the opioid epidemic; and one-third of Americans are unaware that the ACA's open enrollment season has begun.
What We're Reading: Drug Approval Speed; Parkinson's Trial Deaths; Calif. Fines Anthem $5M
An analysis digs into whether the FDA really is approving drugs faster under Commissioner Scott Gottlieb, MD; a clinical trial for a Parkinson's disease drug halts enrollment after 5 deaths; and California fines Anthem $5 million for poor response to consumer complaints.
What We're Reading: Comparing Opioid Treatments; Obamacare Mandate Repeal; Teen Depression
Study finds 2 competing opioid treatments have similar outcomes; GOP tax bill includes repeal of the ACA's individual mandate; and a study finds a correlation between screen time and depression in teenage girls.
What We're Reading: Retroactive Medicaid; Ethical Physician Conduct; Nebraska Mental Health Care
A fourth state has chosen to roll back retroactive Medicaid benefits; the American Medical Association releases guidance for ethical physician conduct in the media; and Nebraska struggles to fund mental health services.